Read our Recent Headlines


Aug 23, 2019 by Jason Chew

Coverage Continuation- ARVN

Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as.

Share 0 Comments Read more
Aug 23, 2019 by Dave Sobek

August 23 Biotech Update

So the sector feels a lot worse than the chart indicates. We are right around support at $80 and that seems to have been holding. We are approaching, however, a.

Aug 21, 2019 by Dave Sobek

August 21 Biotech Update

Broadly speaking the sector and market are doing well. Sentiment has been pretty negative and there were some macro concerns. This seems to be easing a bit, so a rally.

Aug 20, 2019 by Dave Sobek

August 20th Biotech Update

So I do not want to spend a lot of time on macro or the sector as it is the same but we do have some really important news to.

Aug 19, 2019 by Jason Chew

Coverage Continuation- ZGNX

Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited.

Aug 19, 2019 by Dave Sobek

August 19th Biotech News

The market seems to be in a good mood to start the week and I would argue it remains macro driven. I think the hope is that central banks and.

Aug 16, 2019 by Dave Sobek

August 16th Biotech Update

So far the week is ending on a positive note but it is early but not surprising that we see some sort of bounce in the market. I sort of.

More From All Reports

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More